Novel therapies for hepatitis C - one pill fits all?

Nat Rev Drug Discov. 2013 Aug;12(8):595-610. doi: 10.1038/nrd4050. Epub 2013 Jun 28.


Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense research and development efforts, a large number of direct-acting antiviral drugs are now beginning to reach patient care. Accordingly, the way in which care is delivered is evolving at a breath-taking pace. Here, we review the current and upcoming treatment options for HCV, describe the key challenges facing clinicians and drug developers and discuss how the landscape in the HCV arena will change over the coming years.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Clinical Trials as Topic
  • Drug Approval
  • Drug Discovery* / methods
  • Drug Discovery* / trends
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus* / drug effects
  • Hepacivirus* / genetics
  • Hepacivirus* / immunology
  • Hepatitis C / drug therapy*
  • Hepatitis C / genetics
  • Hepatitis C / virology
  • Hepatitis C Antibodies / blood
  • Humans
  • Molecular Targeted Therapy* / methods
  • Molecular Targeted Therapy* / trends
  • Treatment Outcome


  • Antiviral Agents
  • Hepatitis C Antibodies